Human Monoclonal Antibodies against Highly Conserved HR1 and HR2 Domains of the SARS-CoV Spike Protein Are More Broadly Neutralizing

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Elshabrawy, Hatem A ^a   Coughlin, Melissa M ^b   Baker, Susan C ^c   Prabhakar, Bellur S ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS SPIKE PROTEIN;

AMINO ACID SEQUENCE; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; NUCLEOTIDE SEQUENCE; PASSIVE IMMUNIZATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PSEUDOTYPING; RECEPTOR BINDING; SARS CORONAVIRUS; VIRUS ISOLATION; VIRUS NEUTRALIZATION;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; BINDING SITES, ANTIBODY; CROSS REACTIONS; EPITOPE MAPPING; HEK293 CELLS; HUMANS; MEMBRANE GLYCOPROTEINS; NEUTRALIZATION TESTS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; TRANSFECTION; VIRAL ENVELOPE PROTEINS;

SARS CORONAVIRUS;

EID: 84869845241     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050366     Document Type: Article

References (43)

1. Peiris JS, Guan Y, Yuen KY, (2004) Severe acute respiratory syndrome. Nat Med 10: S88-97.
2. He Y, Zhu Q, Liu S, Zhou Y, Yang B, et al. (2005) Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines. Virology 334: 74-82.
3. Li T, Xie J, He Y, Fan H, Baril L, et al. (2006) Long-term persistence of robust antibody and cytotoxic T cell responses in recovered patients infected with SARS coronavirus. PLoS One 1: e24.
4. Xu X, Gao X, (2004) Immunological responses against SARS-coronavirus infection in humans. Cell Mol Immunol 1: 119-122.
5. Yang ZY, Kong WP, Huang Y, Roberts A, Murphy BR, et al. (2004) A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428: 561-564.
6. Guan Y, Zheng BJ, He YQ, Liu XL, Zhuang ZX, et al. (2003) Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 302: 276-278.
7. Kan B, Wang M, Jing H, Xu H, Jiang X, et al. (2005) Molecular evolution analysis and geographic investigation of severe acute respiratory syndrome coronavirus-like virus in palm civets at an animal market and on farms. J Virol 79: 11892-11900.
8. Lau SK, Woo PC, Li KS, Huang Y, Tsoi HW, et al. (2005) Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci U S A 102: 14040-14045.
9. Li W, Shi Z, Yu M, Ren W, Smith C, et al. (2005) Bats are natural reservoirs of SARS-like coronaviruses. Science 310: 676-679.
10. Peiris JS, Chu CM, Cheng VC, Chan KS, Hung IF, et al. (2003) Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 361: 1767-1772.
11. Coughlin MM, Babcook J, Prabhakar BS, (2009) Human monoclonal antibodies to SARS-coronavirus inhibit infection by different mechanisms. Virology 394: 39-46.
12. Rockx B, Corti D, Donaldson E, Sheahan T, Stadler K, et al. (2008) Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge. J Virol 82: 3220-3235.
13. Rockx B, Donaldson E, Frieman M, Sheahan T, Corti D, et al. (2010) Escape from human monoclonal antibody neutralization affects in vitro and in vivo fitness of severe acute respiratory syndrome coronavirus. J Infect Dis 201: 946-955.
14. Wong SK, Li W, Moore MJ, Choe H, Farzan M, (2004) A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J Biol Chem 279: 3197-3201.
15. Tripet B, Howard MW, Jobling M, Holmes RK, Holmes KV, et al. (2004) Structural characterization of the SARS-coronavirus spike S fusion protein core. J Biol Chem 279: 20836-20849.
16. Du L, He Y, Zhou Y, Liu S, Zheng BJ, et al. (2009) The spike protein of SARS-CoV-a target for vaccine and therapeutic development. Nat Rev Microbiol 7: 226-236.
17. Marra MA, Jones SJ, Astell CR, Holt RA, Brooks-Wilson A, et al. (2003) The Genome sequence of the SARS-associated coronavirus. Science 300: 1399-1404.
18. Li F, Li W, Farzan M, Harrison SC, (2005) Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 309: 1864-1868.
19. Coughlin M, Lou G, Martinez O, Masterman SK, Olsen OA, et al. (2007) Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse. Virology 361: 93-102.
20. He Y, Lu H, Siddiqui P, Zhou Y, Jiang S, (2005) Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J Immunol 174: 4908-4915.
21. Ingallinella P, Bianchi E, Finotto M, Cantoni G, Eckert DM, et al. (2004) Structural characterization of the fusion-active complex of severe acute respiratory syndrome (SARS) coronavirus. Proc Natl Acad Sci U S A 101: 8709-8714.
22. Bosch BJ, Bartelink W, Rottier PJ, (2008) Cathepsin L functionally cleaves the severe acute respiratory syndrome coronavirus class I fusion protein upstream of rather than adjacent to the fusion peptide. J Virol 82: 8887-8890.
23. Huang IC, Bosch BJ, Li F, Li W, Lee KH, et al. (2006) SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells. J Biol Chem 281: 3198-3203.
24. Sainz B Jr, Rausch JM, Gallaher WR, Garry RF, Wimley WC, (2005) Identification and characterization of the putative fusion peptide of the severe acute respiratory syndrome-associated coronavirus spike protein. J Virol 79: 7195-7206.
25. Liu IJ, Kao CL, Hsieh SC, Wey MT, Kan LS, et al. (2009) Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors. Antiviral Res 81: 82-87.
26. Lip KM, Shen S, Yang X, Keng CT, Zhang A, et al. (2006) Monoclonal antibodies targeting the HR2 domain and the region immediately upstream of the HR2 of the S protein neutralize in vitro infection of severe acute respiratory syndrome coronavirus. J Virol 80: 941-950.
27. Lai SC, Chong PC, Yeh CT, Liu LS, Jan JT, et al. (2005) Characterization of neutralizing monoclonal antibodies recognizing a 15-residues epitope on the spike protein HR2 region of severe acute respiratory syndrome coronavirus (SARS-CoV). J Biomed Sci 12: 711-727.
28. Chakraborti S, Prabakaran P, Xiao X, Dimitrov DS, (2005) The SARS coronavirus S glycoprotein receptor binding domain: fine mapping and functional characterization. Virol J 2: 73.
29. Zhang H, Wang G, Li J, Nie Y, Shi X, et al. (2004) Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies. J Virol 78: 6938-6945.
30. Keng CT, Zhang A, Shen S, Lip KM, Fielding BC, et al. (2005) Amino acids 1055 to 1192 in the S2 region of severe acute respiratory syndrome coronavirus S protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents. J Virol 79: 3289-3296.
31. Tiffen JC, Bailey CG, Ng C, Rasko JE, Holst J, (2010) Luciferase expression and bioluminescence does not affect tumor cell growth in vitro or in vivo. Mol Cancer 9: 299.
32. Graham RL, Baric RS, (2010) Recombination, reservoirs, and the modular spike: mechanisms of coronavirus cross-species transmission. J Virol 84: 3134-3146.
33. Song HD, Tu CC, Zhang GW, Wang SY, Zheng K, et al. (2005) Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human. Proc Natl Acad Sci U S A 102: 2430-2435.
34. Zhong X, Yang H, Guo ZF, Sin WY, Chen W, et al. (2005) B-cell responses in patients who have recovered from severe acute respiratory syndrome target a dominant site in the S2 domain of the surface spike glycoprotein. J Virol 79: 3401-3408.
35. Lip KM, Shen S, Yang X, Keng CT, Zhang A, et al. (2006) Monoclonal antibodies targeting the HR2 domain and the region immediately upstream of the HR2 of the S protein neutralize in vitro infection of severe acute respiratory syndrome coronavirus. Journal of Virology 80: 941-950.
36. ter Meulen J, van den Brink EN, Poon LL, Marissen WE, Leung CS, et al. (2006) Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med 3: e237.
37. Marasco WA, Sui J, (2007) The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotechnol 25: 1421-1434.
38. Prabakaran M, Prabhu N, He F, Hongliang Q, Ho HT, et al. (2009) Combination therapy using chimeric monoclonal antibodies protects mice from lethal H5N1 infection and prevents formation of escape mutants. PLoS One 4: e5672.
39. McKeating JA, Gow J, Goudsmit J, Pearl LH, Mulder C, et al. (1989) Characterization of HIV-1 neutralization escape mutants. AIDS 3: 777-784.
40. Bakker AB, Marissen WE, Kramer RA, Rice AB, Weldon WC, et al. (2005) Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants. J Virol 79: 9062-9068.
41. Yang H, Zhang J, Wu J, Shou C, (2005) Preparation and characterization of monoclonal antibodies against nucleostemin, a protein that controls cell proliferation in stem cells and cancer cells. Hybridoma (Larchmt) 24: 36-41.
42. Skehel JJ, Wiley DC, (1998) Coiled coils in both intracellular vesicle and viral membrane fusion. Cell 95: 871-874.
43. McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP, et al. (2011) Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature.